 | • レポートコード：GIR-105X12495 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、ニボルマブのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ニボルマブの種類別市場規模（注射4mL、注射10mL）、用途別市場規模（切除不能黒色腫、転移性黒色腫、転移性扁平上皮NSCLC、古典的ホジキンリンパ腫、腎細胞癌、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ニボルマブの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Ono Pharmaceutical、Bristol-Myers Squibb ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：注射4mL、注射10mL ・用途別分析2016年-2026年：切除不能黒色腫、転移性黒色腫、転移性扁平上皮NSCLC、古典的ホジキンリンパ腫、腎細胞癌、その他 ・ニボルマブの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ニボルマブのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ニボルマブのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ニボルマブの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ニボルマブの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Nivolumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Nivolumab size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Nivolumab market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Nivolumab market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Injection 4mL
Injection 10mL
Market segment by Application can be divided into
Unresectable Melanoma
Metastatic Melanoma
Metastatic Squamous NSCLC
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Other
The key market players for global Nivolumab market are listed below:
Ono Pharmaceutical
Bristol-Myers Squibb
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Nivolumab Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Nivolumab Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Injection 4mL
1.2.3 Injection 10mL
1.3 Market Analysis by Application
1.3.1 Overview: Global Nivolumab Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Unresectable Melanoma
1.3.3 Metastatic Melanoma
1.3.4 Metastatic Squamous NSCLC
1.3.5 Classical Hodgkin Lymphoma
1.3.6 Renal Cell Carcinoma
1.3.7 Other
1.4 Global Nivolumab Market Size & Forecast
1.4.1 Global Nivolumab Sales in Value (2016-2026))
1.4.2 Global Nivolumab Sales in Volume (2016-2026)
1.4.3 Global Nivolumab Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Nivolumab Production Capacity Analysis
1.5.1 Global Nivolumab Total Production Capacity (2016-2026)
1.5.2 Global Nivolumab Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Nivolumab Market Drivers
1.6.2 Nivolumab Market Restraints
1.6.3 Nivolumab Trends Analysis
2 Manufacturers Profiles
2.1 Ono Pharmaceutical
2.1.1 Ono Pharmaceutical Details
2.1.2 Ono Pharmaceutical Major Business
2.1.3 Ono Pharmaceutical Nivolumab Product and Services
2.1.4 Ono Pharmaceutical Nivolumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Nivolumab Product and Services
2.2.4 Bristol-Myers Squibb Nivolumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Nivolumab Sales by Manufacturer
3.1 Global Nivolumab Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Nivolumab Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Nivolumab
3.4 Market Concentration Rate
3.4.1 Top 3 Nivolumab Manufacturer Market Share
3.4.2 Top 6 Nivolumab Manufacturer Market Share
3.5 Global Nivolumab Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Nivolumab Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Nivolumab Market Size by Region
4.1.1 Global Nivolumab Sales in Volume by Region (2016-2026)
4.1.2 Global Nivolumab Revenue by Region (2016-2026)
4.2 North America Nivolumab Revenue (2016-2026)
4.3 Europe Nivolumab Revenue (2016-2026)
4.4 Asia-Pacific Nivolumab Revenue (2016-2026)
4.5 South America Nivolumab Revenue (2016-2026)
4.6 Middle East and Africa Nivolumab Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Nivolumab Sales in Volume by Type (2016-2026)
5.2 Global Nivolumab Revenue by Type (2016-2026)
5.3 Global Nivolumab Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Nivolumab Sales in Volume by Application (2016-2026)
6.2 Global Nivolumab Revenue by Application (2016-2026)
6.3 Global Nivolumab Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Nivolumab Sales by Type (2016-2026)
7.2 North America Nivolumab Sales by Application (2016-2026)
7.3 North America Nivolumab Market Size by Country
7.3.1 North America Nivolumab Sales in Volume by Country (2016-2026)
7.3.2 North America Nivolumab Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Nivolumab Sales by Type (2016-2026)
8.2 Europe Nivolumab Sales by Application (2016-2026)
8.3 Europe Nivolumab Market Size by Country
8.3.1 Europe Nivolumab Sales in Volume by Country (2016-2026)
8.3.2 Europe Nivolumab Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Nivolumab Sales by Type (2016-2026)
9.2 Asia-Pacific Nivolumab Sales by Application (2016-2026)
9.3 Asia-Pacific Nivolumab Market Size by Region
9.3.1 Asia-Pacific Nivolumab Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Nivolumab Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Nivolumab Sales by Type (2016-2026)
10.2 South America Nivolumab Sales by Application (2016-2026)
10.3 South America Nivolumab Market Size by Country
10.3.1 South America Nivolumab Sales in Volume by Country (2016-2026)
10.3.2 South America Nivolumab Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Nivolumab Sales by Type (2016-2026)
11.2 Middle East & Africa Nivolumab Sales by Application (2016-2026)
11.3 Middle East & Africa Nivolumab Market Size by Country
11.3.1 Middle East & Africa Nivolumab Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Nivolumab Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Nivolumab Typical Distributors
12.3 Nivolumab Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Nivolumab Revenue by Type, (USD Million), 2021-2026
Table 2. Global Nivolumab Revenue by Application, (USD Million), 2021-2026
Table 3. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 4. Ono Pharmaceutical Major Business
Table 5. Ono Pharmaceutical Nivolumab Product and Services
Table 6. Ono Pharmaceutical Nivolumab Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 8. Bristol-Myers Squibb Major Business
Table 9. Bristol-Myers Squibb Nivolumab Product and Services
Table 10. Bristol-Myers Squibb Nivolumab Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Global Nivolumab Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 12. Global Nivolumab Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 13. Market Position of Manufacturers in Nivolumab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 14. Global Nivolumab Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 15. Head Office and Nivolumab Production Site of Key Manufacturer
Table 16. Global Nivolumab Sales by Region (2016-2021e) & (K Pcs)
Table 17. Global Nivolumab Sales by Region (2021-2026) & (K Pcs)
Table 18. Global Nivolumab Revenue by Region (2016-2021e) & (USD Million)
Table 19. Global Nivolumab Revenue by Region (2021-2026) & (USD Million)
Table 20. Global Nivolumab Sales by Type (2016-2021e) & (K Pcs)
Table 21. Global Nivolumab Sales by Type (2021-2026) & (K Pcs)
Table 22. Global Nivolumab Revenue by Type (2016-2021e) & (USD Million)
Table 23. Global Nivolumab Revenue by Type (2021-2026) & (USD Million)
Table 24. Global Nivolumab Price by Type (2016-2021e) & (USD/Pcs)
Table 25. Global Nivolumab Price by Type (2021-2026) & (USD/Pcs)
Table 26. Global Nivolumab Sales by Application (2016-2021e) & (K Pcs)
Table 27. Global Nivolumab Sales by Application (2021-2026) & (K Pcs)
Table 28. Global Nivolumab Revenue by Application (2016-2021e) & (USD Million)
Table 29. Global Nivolumab Revenue by Application (2021-2026) & (USD Million)
Table 30. Global Nivolumab Price by Application (2016-2021e) & (USD/Pcs)
Table 31. Global Nivolumab Price by Application (2021-2026) & (USD/Pcs)
Table 32. North America Nivolumab Sales by Country (2016-2021e) & (K Pcs)
Table 33. North America Nivolumab Sales by Country (2021-2026) & (K Pcs)
Table 34. North America Nivolumab Revenue by Country (2016-2021e) & (USD Million)
Table 35. North America Nivolumab Revenue by Country (2021-2026) & (USD Million)
Table 36. North America Nivolumab Sales by Type (2016-2021e) & (K Pcs)
Table 37. North America Nivolumab Sales by Type (2021-2026) & (K Pcs)
Table 38. North America Nivolumab Sales by Application (2016-2021e) & (K Pcs)
Table 39. North America Nivolumab Sales by Application (2021-2026) & (K Pcs)
Table 40. Europe Nivolumab Sales by Country (2016-2021e) & (K Pcs)
Table 41. Europe Nivolumab Sales by Country (2021-2026) & (K Pcs)
Table 42. Europe Nivolumab Revenue by Country (2016-2021e) & (USD Million)
Table 43. Europe Nivolumab Revenue by Country (2021-2026) & (USD Million)
Table 44. Europe Nivolumab Sales by Type (2016-2021e) & (K Pcs)
Table 45. Europe Nivolumab Sales by Type (2021-2026) & (K Pcs)
Table 46. Europe Nivolumab Sales by Application (2016-2021e) & (K Pcs)
Table 47. Europe Nivolumab Sales by Application (2021-2026) & (K Pcs)
Table 48. Asia-Pacific Nivolumab Sales by Region (2016-2021e) & (K Pcs)
Table 49. Asia-Pacific Nivolumab Sales by Region (2021-2026) & (K Pcs)
Table 50. Asia-Pacific Nivolumab Revenue by Region (2016-2021e) & (USD Million)
Table 51. Asia-Pacific Nivolumab Revenue by Region (2021-2026) & (USD Million)
Table 52. Asia-Pacific Nivolumab Sales by Type (2016-2021e) & (K Pcs)
Table 53. Asia-Pacific Nivolumab Sales by Type (2021-2026) & (K Pcs)
Table 54. Asia-Pacific Nivolumab Sales by Application (2016-2021e) & (K Pcs)
Table 55. Asia-Pacific Nivolumab Sales by Application (2021-2026) & (K Pcs)
Table 56. South America Nivolumab Sales by Country (2016-2021e) & (K Pcs)
Table 57. South America Nivolumab Sales by Country (2021-2026) & (K Pcs)
Table 58. South America Nivolumab Revenue by Country (2016-2021e) & (USD Million)
Table 59. South America Nivolumab Revenue by Country (2021-2026) & (USD Million)
Table 60. South America Nivolumab Sales by Type (2016-2021e) & (K Pcs)
Table 61. South America Nivolumab Sales by Type (2021-2026) & (K Pcs)
Table 62. South America Nivolumab Sales by Application (2016-2021e) & (K Pcs)
Table 63. South America Nivolumab Sales by Application (2021-2026) & (K Pcs)
Table 64. Middle East & Africa Nivolumab Sales by Country (2016-2021e) & (K Pcs)
Table 65. Middle East & Africa Nivolumab Sales by Country (2021-2026) & (K Pcs)
Table 66. Middle East & Africa Nivolumab Revenue by Country (2016-2021e) & (USD Million)
Table 67. Middle East & Africa Nivolumab Revenue by Country (2021-2026) & (USD Million)
Table 68. Middle East & Africa Nivolumab Sales by Type (2016-2021e) & (K Pcs)
Table 69. Middle East & Africa Nivolumab Sales by Type (2021-2026) & (K Pcs)
Table 70. Middle East & Africa Nivolumab Sales by Application (2016-2021e) & (K Pcs)
Table 71. Middle East & Africa Nivolumab Sales by Application (2021-2026) & (K Pcs)
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Nivolumab Typical Distributors
Table 75. Nivolumab Typical Customers
List of Figures
Figure 1. Nivolumab Picture
Figure 2. Global Nivolumab Sales Market Share by Type in 2020
Figure 3. Injection 4mL
Figure 4. Injection 10mL
Figure 5. Global Nivolumab Sales Market Share by Application in 2020
Figure 6. Unresectable Melanoma
Figure 7. Metastatic Melanoma
Figure 8. Metastatic Squamous NSCLC
Figure 9. Classical Hodgkin Lymphoma
Figure 10. Renal Cell Carcinoma
Figure 11. Other
Figure 12. Global Nivolumab Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 13. Global Nivolumab Market Size and Forecast (2016-2026) & (USD Million)
Figure 14. United States Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Canada Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. Mexico Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Germany Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. France Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. United Kingdom Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Russia Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Italy Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. China Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Japan Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Korea Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. India Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Southeast Asia Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Australia Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Brazil Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Egypt Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Saudi Arabia Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. South Africa Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Turkey Nivolumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. Global Nivolumab Sales (2016-2026) & (K Pcs)
Figure 34. Global Nivolumab Production Capacity (2016-2026) & (K Pcs)
Figure 35. Global Nivolumab Production Capacity by Geographic Region: 2020 VS 2021
Figure 36. Nivolumab Market Drivers
Figure 37. Nivolumab Market Restraints
Figure 38. Nivolumab Market Trends
Figure 39. Global Nivolumab Sales Market Share by Manufacturer in 2020
Figure 40. Global Nivolumab Revenue Market Share by Manufacturer in 2020
Figure 41. Nivolumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 42. Top 3 Nivolumab Manufacturer (Revenue) Market Share in 2020
Figure 43. Top 6 Nivolumab Manufacturer (Revenue) Market Share in 2020
Figure 44. Global Nivolumab Sales Market Share by Region (2016-2026)
Figure 45. Global Nivolumab Revenue Market Share by Region (2016-2026)
Figure 46. North America Nivolumab Revenue (2016-2026) & (USD Million)
Figure 47. Europe Nivolumab Revenue (2016-2026) & (USD Million)
Figure 48. Asia-Pacific Nivolumab Revenue (2016-2026) & (USD Million)
Figure 49. South America Nivolumab Revenue (2016-2026) & (USD Million)
Figure 50. Middle East & Africa Nivolumab Revenue (2016-2026) & (USD Million)
Figure 51. Global Nivolumab Sales Market Share by Type (2016-2026)
Figure 52. Global Nivolumab Revenue Market Share by Type (2016-2026)
Figure 53. Global Nivolumab Price by Type (2016-2026) & (USD/Pcs)
Figure 54. Global Nivolumab Sales Market Share by Application (2016-2026)
Figure 55. Global Nivolumab Revenue Market Share by Application (2016-2026)
Figure 56. Global Nivolumab Price by Application (2016-2026) & (USD/Pcs)
Figure 57. North America Nivolumab Sales Market Share by Country (2016-2026)
Figure 58. North America Nivolumab Revenue Market Share by Country (2016-2026)
Figure 59. North America Nivolumab Sales Market Share by Type (2016-2026)
Figure 60. North America Nivolumab Sales Market Share by Application (2016-2026)
Figure 61. Europe Nivolumab Sales Market Share by Country (2016-2026)
Figure 62. Europe Nivolumab Revenue Market Share by Country (2016-2026)
Figure 63. Europe Nivolumab Sales Market Share by Type (2016-2026)
Figure 64. Europe Nivolumab Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific Nivolumab Sales Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Nivolumab Revenue Market Share by Region (2016-2026)
Figure 67. Asia-Pacific Nivolumab Sales Market Share by Region (2016-2026)
Figure 68. Asia-Pacific Nivolumab Sales Market Share by Application (2016-2026)
Figure 69. South America Nivolumab Sales Market Share by Country (2016-2026)
Figure 70. South America Nivolumab Revenue Market Share by Country (2016-2026)
Figure 71. South America Nivolumab Sales Market Share by Type (2016-2026)
Figure 72. South America Nivolumab Sales Market Share by Application (2016-2026)
Figure 73. Middle East & Africa Nivolumab Sales Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Nivolumab Revenue Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Nivolumab Sales Market Share by Type (2016-2026)
Figure 76. Middle East & Africa Nivolumab Sales Market Share by Application (2016-2026)
Figure 77. Sales Channel: Direct Channel vs Indirect Channel
Figure 78. Methodology
Figure 79. Research Process and Data Source
世界のペンブロリズマブ市場 2021：企業別、地域別、種類・用途別 The Pembrolizumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rece…- 末端部黒子様黒色腫の世界市場2018-2025 Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.In 2018, the global Acral Lentiginous Melanoma market size was xx million US$ and is forecast to xx million US …
- 世界の転移性骨腫瘍治療市場 2021：企業別、地域別、種類・用途別 The Metastatic Bone Tumor Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…
- 末端部黒子様黒色腫トリートメントの世界市場2018-2025 Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.In 2018, the global Acral Lentiginous Melanoma Treatment market size was xx million US$ and is forecast to xx m…
- 末端部黒子様黒色腫薬の世界市場2018-2025 Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.In 2018, the global Acral Lentiginous Melanoma Drugs market size was xx million US$ and is forecast to xx milli…